

# Merck KGaA – Valuation

1/22/2026

<b>Ticker</b>	MRK
<b>Company</b>	Merck KGaA
<b>Currency</b>	EUR
<b>Industry</b>	Drug Manufacturers - Specialty & Generic

Description
Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

<b>Metric</b>	EPS
<b>EPS (ttm)</b>	6.80
<b>Book Value Per Share</b>	68.97
<b>Avg. 5Y Price Change</b>	-3.00%
<b>Cost of Equity</b>	14.00%
<b>Book Value Per Share Growth</b>	11.00%

<b>Earnings Per Share Growth</b>	19.00%
<b>Sales Per Share Growth</b>	6.00%
<b>Operating Cash Flow Per Share Growth</b>	11.00%
<b>Growth Rate</b>	11.00%
<b>Forecasted Growth</b>	<b>2026:</b> 7.55   <b>2027:</b> 8.38   <b>2028:</b> 9.30   <b>2029:</b> 10.32   <b>2030:</b> 11.46   <b>2031:</b> 12.72
<b>Discounted</b>	<b>2026:</b> 6.62   <b>2027:</b> 6.45   <b>2028:</b> 6.28   <b>2029:</b> 6.11   <b>2030:</b> 5.95   <b>2031:</b> 5.79
<b>Terminal Rate</b>	1.00%
<b>Last Close</b>	125.60
<b>Fair Value</b>	82.22
<b>Over/UnderValued %</b>	<b>52.76%</b>